SP500263

03/01/2002 - "The experiments described herein demonstrate that SP500263 is efficacious in the MCF-7 proliferation assay and in a murine model of breast cancer."
03/01/2002 - "Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models."
03/01/2002 - "Therefore, SP500263 is a member of a series of next-generation SERMs with functional selectivity toward ER-alpha and a mixed agonist/antagonist profile in a bone cell assay versus a breast cancer assay. "
03/01/2002 - "In contrast to the results observed in U2OS cells, SP500263 acts as a strong estrogen antagonist in an MCF-7 breast cancer proliferation assay. "
03/01/2002 - "We have compared the antitumor activities of SP500263, a novel next-generation selective estrogen receptor modulator (SERM), tamoxifen, and raloxifene side-by-side in in vitro and in vivo MCF-7 breast cancer models. "

03/01/2002 - "In contrast, SP500263 acts as a strong estrogen agonist in a strictly ER-alpha-specific manner in U2OS osteosarcoma cell lines blocking the production of interleukin (IL) 6 and granulocyte macrophage colony-stimulating factor. "

07/01/2003 - "Furthermore, representatives of the SP500263 family of SERMs may be effective as therapeutics for the treatment of osteoporosis."

03/01/2002 - "To investigate the antitumor activity of SP500263 in animals, athymic nude mice were implanted with MCF-7 tumor in the presence of a tumor growth-supporting sustained release estrogen pellet. "
03/01/2002 - "dosing, effectively reduced estrogen-stimulated tumor growth at 3 and 30 mg/kg. SP500263 was as efficacious as tamoxifen and superior to raloxifene at the corresponding doses. "

06/01/2003 - "SP500263 also antagonized the OVX-induced increase in body weight. "